Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

Stock Information for Monopar Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Monopar Therapeutics Inc.

Tiziana Life Sciences to Ring the Closing Bell at Nasdaq
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer's Clinical Trial
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
Tiziana Life Sciences Announces Withdrawal of Proposed Public Offering
Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer's Trial
Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company
Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program
Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.